The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients

被引:85
作者
Kakizawa, H
Itoh, M
Itoh, Y
Imamura, S
Ishiwata, Y
Matsumoto, T
Yamamoto, K
Kato, T
Ono, Y
Nagata, M
Hayakawa, N
Suzuki, A
Goto, Y
Oda, N
机构
[1] Fujita Hlth Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Toyoake, Aichi 4701192, Japan
[2] Enshu Gen Hosp, Dept Internal Med, Shizuoka, Japan
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2004年 / 53卷 / 05期
关键词
D O I
10.1016/j.metabol.2003.12.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Understanding the causes of diabetic vascular complications has become an increasingly important issue because of the rapidly rising prevalence of diabetes. Recently discovered vasoconstrictors and angiogenesis regulators, such as endothelin (ET) and vascular endothelial growth factor (VEGF), have been intensely studied for possible pathogenic roles in diabetic vascular complications. The present study was undertaken to clarify the effect of glycemic control on serum VEGF and plasma ET-1 concentrations in diabetic patients, and to identify other factors that may cause fluctuations of these substances. Plasma VEGF and ET-1 concentrations of 45 hospitalized diabetic patients and 54 control subjects were measured by enzyme immunoassay (EIA) and radioimmunoassay (RIA), respectively. Plasma VEGF was elevated in poorly controlled diabetic patients compared with healthy subjects and plasma VEGF concentrations declined after hospitalized treatment with either insulin or oral hypoglycemic agents in combination with diet. There was a significant correlation between plasma VEGF concentration and both fasting plasma glucose (FPG) and hemoglobin A(1c) (HbA(1c)). Plasma ET-1 in poorly controlled diabetic patients was higher than in healthy controls, but improved glycemic control did not affect plasma ET-1 concentrations. Thus, poor glycemic control causes increased levels of plasma VEGF, which may result in hypertension and vascular complications in diabetes. Short-term treatment resulting in good glycemic control can improve levels of VEGF and may provide beneficial effects on diabetic vascular complications. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:550 / 555
页数:6
相关论文
共 35 条
[1]   INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY [J].
ADAMIS, AP ;
MILLER, JW ;
BERNAL, MT ;
DAMICO, DJ ;
FOLKMAN, J ;
YEO, TK ;
YEO, KT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) :445-450
[2]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[3]   Role of vascular endothelial growth factor in diabetic vascular complications [J].
Aiello, LP ;
Wong, JS .
KIDNEY INTERNATIONAL, 2000, 58 :S113-S119
[4]  
Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36
[5]   Microvascular permeability is increased in both types of diabetes and correlates differentially with serum levels of insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF) [J].
Brausewetter, F ;
Jehle, PM ;
Jung, MF ;
Boehm, BO ;
Brueckel, J ;
Hombach, V ;
Osterhues, HH .
HORMONE AND METABOLIC RESEARCH, 2001, 33 (12) :713-720
[6]   Haemodynamics in microvascular complications in type 1 diabetes [J].
Candido, R ;
Allen, TJ .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 (04) :286-304
[7]   Increased activity of endogenous endothelin in patients with type II diabetes mellitus [J].
Cardillo, C ;
Campia, U ;
Bryant, MB ;
Panza, JA .
CIRCULATION, 2002, 106 (14) :1783-1787
[8]  
CEDIEL E, 2002, KIDNEY INT S, V82, P2
[9]   Role of vascular endothelial growth factor in diabetic nephropathy [J].
Cha, DR ;
Kim, NH ;
Yoon, JW ;
Jo, SK ;
Cho, WC ;
Kim, HK ;
Won, NH .
KIDNEY INTERNATIONAL, 2000, 58 :S104-S112
[10]  
EASTMAN RC, 2000, DIABETES MELLITUS FU, P746